(Q46893987)

26 December 2017

title

Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome. (English)

1 reference

26 December 2017

0 references

1 reference

1 reference

1 reference

1 reference

Michiyo Deushi

1

1 reference

26 December 2017

Mitsunori Nomura

2

1 reference

26 December 2017

Akio Kawakami

3

1 reference

26 December 2017

Mihoko Haraguchi

4

1 reference

26 December 2017

Mizuho Ito

5

1 reference

26 December 2017

Mitsuyo Okazaki

6

1 reference

26 December 2017

Hideto Ishii

7

1 reference

26 December 2017

Masayuki Yoshida

8

1 reference

26 December 2017

language of work or name

English

0 references

publication date

20 November 2007

1 reference

26 December 2017

published in

FEBS Letters

1 reference

26 December 2017

volume

581

1 reference

26 December 2017

page(s)

5664-5670

1 reference

26 December 2017

issue

29

1 reference

26 December 2017

Absorption and metabolism of dietary cholesterol

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2007.11.023

Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2007.11.023

The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2007.11.023

NPC1L1: evolution from pharmacological target to physiological sterol transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2007.11.023

Deficiency of Niemann-Pick C1 Like 1 prevents atherosclerosis in ApoE-/- mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2007.11.023

Inactivation of NPC1L1 causes multiple lipid transport defects and protects against diet-induced hypercholesterolemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2007.11.023

Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in ApoE knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2007.11.023

Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2007.11.023

Nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2007.11.023

NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2007.11.023

Steatohepatitis: a tale of two "hits"?

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2007.11.023

Insulin resistance in the Zucker diabetic fatty rat: a metabolic characterisation of obese and lean phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2007.11.023

Ezetimibe potently inhibits cholesterol absorption but does not affect acute hepatic or intestinal cholesterol synthesis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2007.11.023

Pitavastatin inhibits remnant lipoprotein-induced macrophage foam cell formation through ApoB48 receptor-dependent mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2007.11.023

Overproduction of large VLDL particles is driven by increased liver fat content in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2007.11.023

Delineation of molecular changes in intrahepatic cholesterol metabolism resulting from diminished cholesterol absorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2007.11.023

Overproduction of VLDL1 driven by hyperglycemia is a dominant feature of diabetic dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2007.11.023

Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of LDL receptor family members

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2007.11.023

Free fatty acids produce insulin resistance and activate the proinflammatory nuclear factor-kappaB pathway in rat liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2007.11.023

Is the slippery slope from steatosis to steatohepatitis paved with triglyceride or cholesterol?

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2007.11.023

Ezetimibe, a potent cholesterol absorption inhibitor, normalizes combined dyslipidemia in obese hyperinsulinemic hamsters

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2007.11.023

Subcutaneous vitamin E ameliorates liver injury in anin vivo model of steatocholestasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2007.11.023

10.1016/J.FEBSLET.2007.11.023

21 January 2018

Identifiers

DOI

1 reference

26 December 2017

PubMed ID

18022391

1 reference

26 December 2017